DS Straus, CK Glass - Trends in Immunology, 2007 - Elsevier The peroxisome proliferator-activated receptors (PPARα, -γ, and -β/δ) are
nuclear receptors with distinct patterns of expression in many cell types both
within and outside the immune system. PPAR ligands have anti-inflammatory ... Cited by 69 - Related articles - All 2 versions
- ►nih.gov JD Lewis, GR Lichtenstein, JJ Deren, BE … - Gastroenterology, 2008 - Elsevier Background & Aims: Thiazolidinedione ligands for the gamma subtype of peroxisome
proliferator-activated receptors (PPARγ), widely used to treat type 2 diabetes
mellitus, have been proposed as novel therapies for ulcerative colitis ... Cited by 25 - Related articles - All 4 versions
IJ Dahabreh - Clinical Trials, 2008 - ctj.sagepub.com Background A meta-analysis of randomized controlled trials suggested that
rosiglitazone, a drug used for the treatment of diabetes, may be associated with
an increased risk of cardiovascular adverse events. Three large randomized ... Cited by 22 - Related articles - BL Direct - All 2 versions
- ►ahajournals.org DK McGuire, SE Inzucchi - Circulation, 2008 - Am Heart Assoc The cardiovascular disease (CVD) risk associated with diabetes mellitus (DM) has
become increasingly evident, accounting for 80% of deaths among patients with
this disease 1 and making CVD risk modification a key therapeutic objective ... Cited by 21 - Related articles - All 6 versions
- ►geyseco.info [PDF] E Selvin, S Bolen, HC Yeh, C Wiley, LM … - Archives of Internal Medicine, 2008 - Am Med Assoc Methods We searched MEDLINE, EMBASE, and the Cochrane Central Register of
Controlled Trials, from inception through January 19, 2006. Forty publications
of controlled trials that reported information on cardiovascular events ( ... Cited by 23 - Related articles - All 5 versions
- ►procampus.net [PDF] - Free from Publisher ZT Bloomgarden - Diabetes Care, 2008 - Am Diabetes Assoc At a symposium on the evaluation of cardiac ischemia and macrovascular disease
in patients with diabetes held at the American Diabetes Association (ADA)
meeting, Theodore Mazzone (Chicago, IL) discussed approaches to subclinical ... Cited by 17 - Related articles - BL Direct - All 8 versions
J Sanz, PR Moreno, V Fuster - Journal of the American College of Cardiology, 2009 - Elsevier The trends in risk factor control in industrialized regions between 1998 and
2006 were evaluated in more than 100,000 patients from the US and 4 European
countries. Although there were modest improvements, large proportions of ... Cited by 16 - Related articles - BL Direct - All 41 versions
- ►geyseco.info [PDF] PD Home, SJ Pocock, H Beck-Nielsen, PS … - The Lancet, 2009 - Elsevier 321 people in the rosiglitazone group and 323 in the active control group
experienced the primary outcome during a mean 5·5-year follow-up, meeting the
criterion of non-inferiority (HR 0·99, 95% CI 0·85–1·16). HR was 0·84 ... Cited by 18 - Related articles - All 40 versions
- ►nursing2008.com E Mannucci, M Monami, C Lamanna, GF … - Diabetes, Obesity and Metabolism, 2008 - pt.wkhealth.com Aim: The aim of this meta-analysis of randomized clinical trials (RCT) was to
assess whether pioglitazone is also associated with increased cardiovascular
risk, as recently reported for rosiglitazone. Methods: RCT of pioglitazone ... Cited by 14 - Related articles - All 6 versions
- ►onlinejacc.org G Orasanu, O Ziouzenkova, PR Devchand, V … - Journal of the American College of Cardiology, 2008 - Elsevier The thiazolidinediones (TZDs) pioglitazone and rosiglitazone are
insulin-sensitizing PPARγ agonists used to treat type 2 diabetes (T2DM).
Despite evidence for TZDs limiting inflammation and atherosclerosis, ... Cited by 13 - Related articles - All 27 versions
